Quarterly Update
26/07/2022 07:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220726:nRSZ6785Ta&default-theme=true RNS Number : 6785T RTW Venture Fund Limited 26 July 2022 LEI: 549300Q7EXQQH6KF7Z84 26 July 2022 RTW Venture Fund Limited Quarterly Update RTW Venture Fund Limited (the "Company") is pleased to announce the Fact Sheet for the quarter ended 30 June 2022 is now available on the Company's website in the Document Library Section www.rtwfunds.com/venture-fund (http://www.rtwfunds.com/venture-fund) . For Further Information RTW Investments, LP +44 (0) 77 1741 7711 Woody Stileman, Managing Director Stephanie Sirota, Chief Business Officer Elysium Fund Management Limited +44 (0) 14 8181 0100 Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director J.P. Morgan Cazenove +44 (0)20 7742 4000 William Simmonds Jérémie Birnbaum James Bouverat (Sales) BofA Securities +44 (0) 20 7628 1000 Edward Peel Kieran Millar About RTW Venture Fund Limited: RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund Limited invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the RTW website at www.rtwfunds.com (https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END MSCBRGDRUBDDGDU